Key Takeaways
- • Digital asset manager Parataxis Holdings has confirmed a merger with SilverBox Corp IV that will take it public at a $400 million equity valuation, according to a company press release issued Wednesday, August 6, 2025.
- • At a $10 share price, the deal could double in valuation if Parataxis exercises a right to raise an additional $400 million through a share purchase agreement.
- • Parataxis has already raised about $31 million, earmarked for purchasing bitcoin ahead of its NYSE listing under the planned ticker PRTX.
- • The firm is expanding into South Korea through its June acquisition of a controlling stake in KOSDAQ-listed Bridge Biotherapeutics, which will be renamed Parataxis Korea; Bridge shares have reportedly jumped 350% since the announcement.
- • The transaction remains subject to shareholder approval and SEC review.
Summary
Digital asset manager Parataxis Holdings is going public through a SPAC merger with SilverBox Corp IV, confirming earlier plans to list. The newly formed entity, Parataxis Holdings Inc., aims to trade on the New York Stock Exchange under the ticker "PRTX." At a $10 share price, the combined company is valued at $400 million, with potential to double that figure if Parataxis exercises its right to raise an additional $400 million through a share purchase agreement. Approximately $31 million has already been raised and earmarked for purchasing bitcoin, giving future shareholders immediate exposure to the asset, according to the company.
Parataxis runs an active bitcoin strategy that combines market exposure with yield-generating techniques, rather than simply holding BTC. The firm says it seeks income through low-volatility trading and treasury-style operations. The platform is run by veterans of Parataxis Capital Management and serves institutional clients, including pension firms and family offices. The SPAC transaction will also allow the firm to expand its U.S. treasury operations and explore other "special situations" investments. If successful, Parataxis could become one of the few publicly listed companies offering direct, active bitcoin exposure outside of an ETF structure.
The company's international push began in June, when it acquired a controlling stake in Bridge Biotherapeutics, a healthcare firm listed on South Korea's KOSDAQ. The company will be renamed Parataxis Korea and serve as a regional base for its bitcoin treasury strategy. Parataxis cited South Korea's large user base, political support for digital assets, and the absence of a spot bitcoin ETF as reasons the market is fertile for bitcoin-focused public firms. The company also pointed to Japan, where Metaplanet's share price has surged after its pivot to bitcoin.
The transaction is expected to close pending shareholder approval and a review by the Securities and Exchange Commission.
Parataxis runs an active bitcoin strategy that combines market exposure with yield-generating techniques, rather than simply holding BTC. The firm says it seeks income through low-volatility trading and treasury-style operations. The platform is run by veterans of Parataxis Capital Management and serves institutional clients, including pension firms and family offices. The SPAC transaction will also allow the firm to expand its U.S. treasury operations and explore other "special situations" investments. If successful, Parataxis could become one of the few publicly listed companies offering direct, active bitcoin exposure outside of an ETF structure.
The company's international push began in June, when it acquired a controlling stake in Bridge Biotherapeutics, a healthcare firm listed on South Korea's KOSDAQ. The company will be renamed Parataxis Korea and serve as a regional base for its bitcoin treasury strategy. Parataxis cited South Korea's large user base, political support for digital assets, and the absence of a spot bitcoin ETF as reasons the market is fertile for bitcoin-focused public firms. The company also pointed to Japan, where Metaplanet's share price has surged after its pivot to bitcoin.
The transaction is expected to close pending shareholder approval and a review by the Securities and Exchange Commission.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.